Privacy Policy

Jazz Pharmaceuticals, Inc., is committed to providing its users with an Internet experience that respects and protects their personal privacy choices and concerns. We have created this privacy statement in order to demonstrate our firm commitment to privacy. The following discloses our information gathering and dissemination practices for this Web site. This site contains links to other sites. Jazz Pharmaceuticals, Inc., is not responsible for the privacy practices or the content of such Web sites.

Your Privacy Rights

Jazz Pharmaceuticals, Inc., is committed to keeping your information private and confidential. Please be assured that Jazz Pharmaceuticals, Inc., does not sell or release any personal information of Web site visitors to any third party.

Traffic Data Collected

When you use our site, we collect anonymous information. Anonymous information is information about how you use our site (such as places visited and searches performed). Anonymous information also includes the domain names and/or IP addresses of browsers that visit our site, time of day the site was visited, and other non-personally identifiable information. Anonymous information is information that is not tied to any individual, but helps to characterize users to improve our services.

Personal Information Collected

Our site uses an order form for customers to request information, products, and services. We collect a visitor's contact information (such as an e-mail address, phone numbers, names, mailing address, etc.). This information is only used to fulfill order requests.

The visitor's contact information is also used to get in touch with the visitor when necessary. For example, we might have a question about the processing of an order. If a user so requests, we may use the contact information to send the user additional information.

The personally identifiable information we collect is not used for any purposes other than order fulfillment and dissemination of information. It is not disclosed to anyone other than Jazz Pharmaceuticals, Inc., and its partners, contractors and agents, unless we must do so to comply with a court order or other legal process, or we must do so to protect our rights or property.

Please note that Jazz Pharmaceuticals, Inc., will not intentionally share the contents of any email or form submitted through this site with any third party. However, due to the nature of electronic communications, we cannot and do not provide assurances that the contents will not become known or accessible to third parties.

Contacting the Web Site

If you have any questions about this privacy statement, the practices of this site, or your dealings with this Web site, you may contact:

Jazz Pharmaceuticals
3180 Porter Drive
Palo Alto, CA 94304

Updates and Changes to Privacy Policy

We reserve the right, at any time to add to, change, update or modify this privacy policy, simply by posting such change, update or modification on the site. Any such change, update or modification will be effective immediately upon posting.

Important Safety Information

1. XYREM^® is a controlled substance. Controlled substances are medicines that, if abused, may lead to varying degrees of physical or psychological dependence. XYREM is a Schedule III drug — which means that it has a moderate dependence liability. If you sell, distribute, or give your XYREM to anyone else or use it for purposes other than what it was prescribed for, you may be punished under federal and state law by jail and fines.

2. It is very important to keep XYREM out of reach of children and pets.

3. XYREM can cause serious side effects including trouble breathing while asleep, confusion, abnormal thinking, depression and loss of consciousness. Tell your doctor if you have any of these problems while taking XYREM.

BOXED WARNING:

!Warning

Central Nervous System Depressant with Abuse Potential. Should not be used with alcohol or other CNS depressants. Sodium oxybate is a form of GHB, a known drug of abuse. Abuse has been associated with some important central nervous system (CNS) adverse events (including death). Even at recommended doses, use has been associated with confusion, depression, and other neuropsychiatric events. Reports of respiratory depression occurred in clinical trials. Almost all of the patients who received sodium oxybate during clinical trials were receiving CNS stimulants.

Important CNS adverse events associated with abuse of GHB include seizure, respiratory depression and profound decreases in level of consciousness, with instances of coma and death. For events that occurred outside of clinical trials, in people taking GHB for recreational purposes, the circumstances surrounding the events are often unclear (e.g., dose of GHB taken, the nature and amount of alcohol or any concomitant drugs).

XYREM is available through the XYREM Success Program^®, using a centralized pharmacy 1-866-XYREM88^® (1-866-997-3688). The Success Program provides educational materials to the prescriber and the patient explaining the risks and proper use of sodium oxybate, and the required prescription form. Once it is documented that the patient has read and/or understood the materials, the drug will be shipped to the patient. The XYREM Success Program also recommends patient follow-up every 3 months. Physicians are expected to report all serious adverse events to the manufacturer.